|
|
Gilead Sciences Inc (GILD) |
|
|
|
| |
GILD's Operating Income Growth by Quarter and Year
Gilead Sciences Inc 's Operating Income results by quarter and year
|
Select the Comparisons :
|
|
Select the Ratio:
|
Operating Income Growth Y/Y▼
|
Operating Income Growth Y/Y▼
|
| GILD Operating Income (in millions $) |
FY 2023 |
FY 2022 |
FY 2021 |
FY 2020 |
| IV Quarter |
December |
-
|
2,267.00
|
940.00
|
2,651.00
|
| III Quarter |
September |
2,623.00
|
2,837.00
|
3,842.00
|
2,001.00
|
| II Quarter |
June |
1,665.00
|
2,029.00
|
2,246.00
|
-2,983.00
|
| I Quarter |
March |
1,705.00
|
197.00
|
2,890.00
|
2,402.00
|
| FY |
|
5,993.00
|
7,330.00
|
9,918.00
|
4,071.00
|
| GILD Operating Income third quarter 2023 Y/Y Growth Comment |
Gilead Sciences Inc reported decrease in Operating Income in the third quarter 2023 by -7.54% to $ 2,623.00 millions, from the same quarter in 2022.
The decrease in the third quarter 2023 Gilead Sciences Inc 's Operating Income compares unfavorably to the Company's average Operating Income jump of 50.67%.
Looking into third quarter 2023 results within Biotechnology & Pharmaceuticals industry 3 other companies have achieved higher Operating Income growth. While Gilead Sciences Inc ' s Operating Income decline of -7.54% ranks overall at the positon no. 937 in the third quarter 2023.
Explain Operating Income growth
|
| GILD Operating Income ( Y/Y Growth %) |
2023
|
2022 |
2021 |
2020 |
| IV Quarter |
December |
- |
141.17 % |
-64.54 % |
142.54 % |
| III Quarter |
September |
-7.54 % |
-26.16 % |
92 % |
- |
| II Quarter |
June |
-17.94 % |
-9.66 % |
- |
- |
| I Quarter |
March |
765.48 % |
-93.18 % |
20.32 % |
7.38 % |
| FY |
|
- |
-26.09 % |
143.63 % |
-5.04 % |
GILD Operating Income (Quarter on Quarter Growth %) |
2023
|
2022 |
2021 |
2020 |
| IV Quarter |
December |
- |
-20.09 % |
-75.53 % |
32.48 % |
| III Quarter |
September |
57.54 % |
39.82 % |
71.06 % |
- |
| II Quarter |
June |
-2.35 % |
929.95 % |
-22.28 % |
- |
| I Quarter |
March |
-24.79 % |
-79.04 % |
9.02 % |
119.76 % |
| FY (Year on Year) |
|
- |
-26.09 % |
143.63 % |
-5.04 % |
| Operating Income Y/Y Growth Statistics |
| High |
Average |
Low |
| 2464.91 % |
50.67 % |
-168.29 % |
| (Sep. 30, 2008) |
|
(Dec. 31, 2006) |
|
|
| Operating Income Y/Y Growth Statistics |
| High |
Average |
Low |
| 2464.91 % |
50.67 % |
-168.29 % |
| (Sep. 30, 2008) |
|
(Dec. 31, 2006) |
|
| Operating Income by Quarter for the Fiscal Years 2020, 2021, 2022, 2023 |
Gilead Sciences Inc 's Q/Q Operating Income Growth
| Operating Income Q/Q Growth Statistics |
| High |
Average |
Low |
| 929.95 % |
20.98 % |
-84.25 % |
| (Jun 30 2022) |
|
|
| GILD's III. Quarter Q/Q Operating Income Comment |
Gilead Sciences Inc achieved in the III. Quarter 2023 above company average sequential Operating Income jump of 57.54%, to $ 2,623.00 millions, from $1,665.00 millions in the second quarter.
Biotechnology & Pharmaceuticals company is undergoing a remarkable growth, not only recording higher then regular increase, but also increasing pace.
Within Biotechnology & Pharmaceuticals industry Gilead Sciences Inc achieved highest sequential Operating Income growth. While Gilead Sciences Inc 's Operating Income growth quarter on quarter, overall rank is 175. |
|
|
|
| Operating Income Q/Q Growth Statistics |
| High |
Average |
Low |
| 929.95 % |
20.98 % |
-84.25 % |
| (Jun 30 2022) |
|
|
| GILD's III. Quarter Q/Q Operating Income Comment |
Gilead Sciences Inc achieved in the III. Quarter 2023 above company average sequential Operating Income jump of 57.54%, to $ 2,623.00 millions, from $1,665.00 millions in the second quarter.
Gilead Sciences Inc is undergoing a remarkable growth, with recording above regular gain, and additionally accelerating rate.
Within Biotechnology & Pharmaceuticals industry Gilead Sciences Inc achieved highest sequential Operating Income growth. While Gilead Sciences Inc 's Operating Income growth quarter on quarter, overall rank is 175. |
|
Gilead Sciences Inc 's 12 Months Operating Income Growth Year on Year
Operating Income TTM Growth |
12 Months Ending
(Sep 30 2023) |
12 Months Ending
(Jun 30 2023) |
12 Months Ending
(Mar 31 2023) |
12 Months Ending
(Dec 31 2022) |
12 Months Ending
(Sep 30 2022) |
| Cumulative Operating Income 12 Months Ending |
$ 8,260.00 |
$ 8,474.00 |
$ 8,838.00 |
$ 7,330.00 |
$ 6,003.00 |
| Y / Y Operating Income Growth (TTM) |
37.6 % |
20.92 % |
22.33 % |
-26.09 % |
-48.38 % |
| Year on Year Operating Income Growth Overall
Ranking |
# 1209 |
# 1472 |
# 313 |
# 121 |
# 1335 |
| Seqeuential Operating Income Change (TTM) |
-2.53 % |
-4.12 % |
20.57 % |
22.11 % |
-14.34 % |
| Seq. Operating Income Growth (TTM) Overall
Ranking |
# 937 |
# 1089 |
# 1393 |
# 1290 |
# 1414 |
| Cumulative Operating Income growth
Comment |
Although Gilead Sciences Inc 's Annual Operating Income growth year on year were below company's average 50.67% , Operating Income announced in the Sep 30 2023 period, show improvement in Operating Income trend, to cumulative trailing twelve month growth of 37.6% year on year, from 20.92% in Jun 30 2023.
In the Healthcare sector 76 other companies have achieved higher trailing twelve month Operating Income growth. While Total ranking has impoved so far to 1209, from total ranking in previous quarter at 1472. |
| Operating Income TTM Q/Q Growth Statistics |
| High |
Average |
Low |
2464.91 % |
50.67 % |
-168.29 % |
|
|
|
|
|
| Operating Income TTM Y/Y Growth Statistics |
| High |
Average |
Low |
2464.91 % |
50.67 % |
-168.29 % |
|
|
|
| Operating Income TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 4 |
| Sector |
# 55 |
| S&P 500 |
# 937 |
|
| Cumulative Operating Income growth
Comment |
Although Gilead Sciences Inc 's Annual Operating Income growth year on year were below company's average 50.67% , Operating Income announced in the Sep 30 2023 period, show improvement in Operating Income trend, to cumulative trailing twelve month growth of 37.6% year on year, from 20.92% in Jun 30 2023.
In the Healthcare sector 76 other companies have achieved higher trailing twelve month Operating Income growth. While Total ranking has impoved so far to 1209, from total ranking in previous quarter at 1472. |
| Operating Income TTM Q/Q Growth Statistics |
| High |
Average |
Low |
2464.91 % |
50.67 % |
-168.29 % |
|
|
|
| Operating Income TTM Y/Y Growth Statistics |
| High |
Average |
Low |
2464.91 % |
50.67 % |
-168.29 % |
|
|
|
| Operating Income TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 4 |
| Sector |
# 55 |
| S&P 500 |
# 937 |
|
